Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial

ConclusionsGalcanezumab was effective and safe during open-label treatment in patients who had experienced failures of previous migraine preventives.Clinical Trial RegistrationClinicalTrials.gov identifier NCT03559257.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research